Lilly forced to halt two prasugrel studies

Eli Lilly and Co. announced Wednesday its suspension of two small trials of prasugrel, a blood-thinning drug it developed with Daiichi Sankyo Co., due to dosage concerns. The company said the studies will remain suspended until their procedures are modified, but affirmed its plan to seek FDA approval for the drug by the end of the year.

View Full Article in:

Wall Street Journal (tiered subscription model), The · CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI